Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy

Mayo Clinic Proceedings

Volumn 74, Issue 12, 1999, Pages 1214-1220

  Brown, James A ^a,c   Slezak, Jeffrey M ^b   Lieber, Michael M ^c   Jenkins, Robert B ^d  

^a Department of Urology ^*  (United States)

^b Section of Biostatistics   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d DAVID GRANT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 4; CHROMOSOME 7; CHROMOSOME 8; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; PROSTATE CANCER; PROSTATECTOMY;

EID: 0032732791     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.12.1214     Document Type: Article

References (51)

1. Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB. Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma. J Ural. 1994; 152:1157-1162.
2. Takahashi S, Qian J, Brown JA, et al. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res. 1994;54:3574-3579.
3. Alcaraz A, Takahashi S, Brown JA, et al. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res. 1994;54:3998-4002.
4. Takahashi S, Alcaraz A, Brown JA, et al. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pT3NOMO) prostate carcinoma. Clin Cancer Res. 1996;2:137-145.
5. Qian J, Bostwick DC, Takahashi S, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. I995;55:54085414.
6. Persons DL, Gibney DJ, Katzmann JA, Lieber MM, Farrow GM, Jenkins RB. Use of fluorescent in situ hybridization for deoxyribonucleic acid ploidy analysis of prostatic adenocarcinoma. J Urol. 1993; 150:120-125.
7. Blute ML, Bostwick DG, Bergstralh EJ. et al. Anatomic sitespecific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997;50: 733-739.
8. Vesalainen S, Nordling S, Lipponen P, Talja M, Syrjanen K. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy. Br] Cancer. 1994;70:309-314.
9. Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI. Prognostic factors in men with stage D l prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol. 1994:152:1077-1081.
10. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993:71:3582-3593.
11. Davidson PJT, Hop W, Kurth KH, Fossa SD, Waehre H, Schröder FH, European Organization for Research and Treatment of Cancer Genitourinary Group. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage TO to 4,N1 to 3,MO,D1). J Urol. 1995:154:2118-2122.
12. Click AJ, Philput CB, el Mahdi A, Ladaga L, Schellhammer PF. Are three substages of clinical B prostate carcinoma useful in predicting disease-free survival? Urology. 1990:36:483487.
13. Zagars GK, Geara FB, Pollack A, von Eschenbach AC. The T classification of clinically localized prostate cancer: an appraisal based on disease outcome after radiation therapy. Cancer. 1994:73:1904-1912.
14. Wu WJ, Huang MS, Wang HJ, Chiang PH, Huang CH, Chiang CP. Flow cytometric DNA analysis of advanced prostatic adenocarcinoma. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih. 1993;9:122130.
15. Oefelein MG, Grayhack JT, McVary KT. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate. Cancer. 1995;76:2535-2542.
16. Haugen OA, Mjolnerod O. DNA-ploidy as prognostic factor in prostatic carcinoma. Int J Cancer. 1990;45:224-228.
17. Grayhack JT, Assimos DG. Prognostic significance of tumor grade and stage in the patient with carcinoma of the prostate. Prostate. 1983:4:13-31.
18. Centeno BA, Zietman AL, Shipley WU, et al. Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. Int J Radial Oncol Biol Phys. 1994:30:309-315.
19. Nielsen K, Overgaard J, Bentzen SM, Bruun E. Histological grade, DNA ploidy and mean nuclear volume as prognostic factors in prostatic cancer. APMIS. 1993;101:614-620.
20. Visakorpi T, Kallioniemi OP, Paronen IY, Isola JJ, Heikkinen AI, Koivula TA. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. Br J Cancer. 1991;64:578-582.
21. Nordgren H, Nilsson S, Eklöv S, et al. Modal DNA values and estramustine-binding protein (EMBP) as prognostic markers in prostatic cancer. Acta Oncol. 1991;30:211-214.
22. Zincke H, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol. 1994; 12:22542263.
23. Robertson CN, Paulson DF. DNA in radical prostatectomy specimens: prognostic value of tumor ploidy. Acta Oncol. 1991:30:205207.
24. Lee SE, Currin SM, Paulson DF, Walther PJ. Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol. 1988; 140:769774.
25. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol. 1993:150:135141.
26. Bostwick DG, Graham SD Jr, Napalkov P, et al. Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology. 1993;41:403-411.
27. Epstein JI, Oesterling JE, Walsh PC. Tumor volume versus percentage of specimen involved by tumor correlated with progression in stage A prostatic cancer. J Urol. 1988:139:980-984.
28. Pollack A, Zagars GK, el-Naggar AK, Terry NH. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology. 1994;44:711-718.
29. van den Ouden D, Tribukait B, Blom JH, et al, European Organization for Research and Treatment of Cancer Genitourinary Group. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. J Urol. 1993:150:400-406.
30. Rainwater LM, Zincke H. Radical prostatectomy after radiation therapy for cancer of the prostate: feasibility and prognosis. J Urol. 1988:140:1455-1459.
31. Yokogi H, Mizutani M, Ishibe T. Flow cytometric DNA analysis of stage D2 prostatic carcinoma. Urol Int. 1991:47:57-59.
32. Hanks GE, Hanlon AL, Hudes G, Lee WR, Suasin W, Schultheiss TE. Patterns-üf-failure analysis of patients with high pretreattnent prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. J. Clin Oncol. 1996; 14:1093-1097.
33. Zietman AL, Dallow KC, McManus PA, Heney NM, Shipley WU. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology. 1996;47:236-239.
34. Riedl CR, Huebner WA, Mossig H, Ogris E, Pflueger H. Prognostic value of prostate-specific antigen minimum after orchidectomy in patients with stage C and D prostatic carcinoma. Br J Urol. 1995; 76:34-40.
35. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol. 1995; 13:464-469.
36. Pisansky TM, Cha SS, Earle JD, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1993; 11:2158-2166.
37. Reynard JM, Peters TJ, Gillatt D. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer-a multivariable analysis of prostate cancer mortality. Br J Urol. 1995;75:507515.
38. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP, Braswell NT. Prostate-specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J Urol. 1995;153:1860-1865.
39. Pollack A, Zagars GK, el-Naggar AK, Gauwitz MD, Terry NH. Near-diploidy : a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer. 1994:73:1895-1903.
40. Blatstein LM, Ginsberg PC, Daskal I, Finkelstein LH. Flow cytometric determination of ploidy in prostatic adenocarcinoma and its relation to clinical outcome. J Am Osteopath Assoc. 1993; 93:463-468,471-472.
41. Wirth MP, Muller HA, Manseck A, Müller J, Frohmuller HG. Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy. Eur Urol, 1991 ;20:248-252.
42. Eskelinen M. Lipponen P. Majapuro R, Syrjanen K, Nordling S. DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma. Eur Ural. 1991;20:62-66.
43. Montgomery BT, Nativ O, Blute ML, et al. Stage B prostate adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. ArchSurg. 1990:125:327-331.
44. Nativ 0. Winkler HZ, Raz Y, et al. Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Mayo Clin Proc. 1989;64:911-919.
45. Tinari N, Natoli C, Angelucci D, et al. DNA and S-phase fraction analysis by flow cytometry in prostate cancer: clinicopathologic implications. Cancer. 1993;71:1289-1296.
46. Miller J, Horsfall DJ, Marshall VR, Rao DM, Leong SY. The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma. J Urol. 1991;145:1192-1196.
47. Lundberg S, Carstensen J, Rundquist I. DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study. Cancer Res. 1987;47:1973-1977.
48. Bratt O, Anderson H, Bak-Jensen E, Baldetorp B, Lundgren R. Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. Urology. 1996:47:218-224.
49. Jones EC, McNeal J, Bruchovsky N, de Jong G. DNA content in prostatic adenocarcinoma: a flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node métastases. Cancer. 1990;66:752-757.
50. Adolfsson J, Tribukait B. Modal DNA-values in prostate cancer patients with deferred therapy or endocrine therapy. Acta Oncol. 1991-,30:209-210.
51. Lifson B, Pizzolo JG, Elhosseiny AA, Choudhury MS, Melamed MR. Comparison of fluorescence in situ hybridization and flow cytometric DNA ploidy analysis in paraffin-embedded prostatic adenocarcinoma specimens. Anal Quant Cylol Histol. 1995;17:9399.